Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer

NCT05659732 is registered in ClinicalTrials.gov with PharmaEngine as lead sponsor.

NCT NCT05659732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05659732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of PEP07 (Checkpoint Kinase 1 Inhibitor) in Patients With Advanced Cancer
Lead sponsor
PharmaEngine
Phase
Phase 1
Overall status
Recruiting
Start date
July 17, 2023
Completion date
December 31, 2026
Enrollment
32 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, lymphoma, mantle-cell